Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: V03AE

BindRen(colestilan)

Hyperphosphatemia

Marketing Authorisation Holder: Mitsubishi Pharma Europe Ltd

EMA Authorisation: 21/01/2013

INN: colestilan

Indication

Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about BindRen — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.